Insider Selling: Abeona Therapeutics (NASDAQ:ABEO) SVP Sells $50,482.74 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) SVP Brendan O’malley sold 9,366 shares of Abeona Therapeutics stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $50,482.74. Following the completion of the transaction, the senior vice president directly owned 350,763 shares in the company, valued at approximately $1,890,612.57. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $5.41 on Friday. The stock’s 50 day moving average is $6.36 and its 200 day moving average is $5.92. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 6.65. The firm has a market cap of $277.42 million, a P/E ratio of 7.73 and a beta of 1.42. Abeona Therapeutics Inc. has a one year low of $3.93 and a one year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $21.71 million. As a group, research analysts expect that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in shares of Abeona Therapeutics during the second quarter worth approximately $25,000. Legal & General Group Plc bought a new stake in Abeona Therapeutics during the second quarter worth $27,000. Riverwater Partners LLC bought a new stake in Abeona Therapeutics during the second quarter worth $62,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Abeona Therapeutics during the second quarter worth $63,000. Finally, Cannon Global Investment Management LLC bought a new stake in Abeona Therapeutics during the first quarter worth $67,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABEO has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Abeona Therapeutics in a research note on Saturday, September 27th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, August 18th. Finally, Oppenheimer boosted their price target on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.